Quoin Pharmaceuticals Ltd DRC (NASDAQ:QNRX) — Market Cap & Net Worth
Market Cap & Net Worth: Quoin Pharmaceuticals Ltd DRC (QNRX)
Quoin Pharmaceuticals Ltd DRC (NASDAQ:QNRX) has a market capitalization of $9.62 Million ($9.62 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27259 globally and #5634 in its home market, demonstrating a 2.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Quoin Pharmaceuticals Ltd DRC's stock price $6.88 by its total outstanding shares 2008418 (2.01 Million). Also see Quoin Pharmaceuticals Ltd DRC (QNRX) total assets for a full breakdown of the balance sheet.
Quoin Pharmaceuticals Ltd DRC Market Cap History: 2016 to 2026
Quoin Pharmaceuticals Ltd DRC's market capitalization history from 2016 to 2026. Data shows change from $18.62 Billion to $13.82 Million (-53.16% CAGR). Also see QNRX cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Quoin Pharmaceuticals Ltd DRC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #771 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2508 of 3165 |
Weight: Quoin Pharmaceuticals Ltd DRC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Quoin Pharmaceuticals Ltd DRC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Quoin Pharmaceuticals Ltd DRC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check QNRX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
-45189.41x
Quoin Pharmaceuticals Ltd DRC's market cap is -45189.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
826.08x
Quoin Pharmaceuticals Ltd DRC's market cap is 826.08 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $18.62 Billion | $-280.00K | $15.32 Million | -66492.98x | 1215.51x |
| 2018 | $12.65 Billion | $-280.00K | $15.32 Million | -45189.41x | 826.08x |
Competitor Companies of QNRX by Market Capitalization
Companies near Quoin Pharmaceuticals Ltd DRC in the global market cap rankings as of September 18, 2026. Review Quoin Pharmaceuticals Ltd DRC tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Quoin Pharmaceuticals Ltd DRC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Quoin Pharmaceuticals Ltd DRC Historical Marketcap From 2016 to 2026
Between 2016 and today, Quoin Pharmaceuticals Ltd DRC's market cap moved from $18.62 Billion to $ 13.82 Million, with a yearly change of -53.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.82 Million | -52.32% |
| 2025 | $28.98 Million | +2117.61% |
| 2024 | $1.31 Million | -86.73% |
| 2023 | $9.85 Million | -71.21% |
| 2022 | $34.22 Million | -93.76% |
| 2021 | $548.30 Million | -78.94% |
| 2020 | $2.60 Billion | -2.69% |
| 2019 | $2.67 Billion | -78.86% |
| 2018 | $12.65 Billion | -70.00% |
| 2017 | $42.18 Billion | +126.54% |
| 2016 | $18.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Quoin Pharmaceuticals Ltd DRC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.62 Million USD |
| MoneyControl | $9.62 Million USD |
| MarketWatch | $9.62 Million USD |
| marketcap.company | $9.62 Million USD |
| Reuters | $9.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more